BIRLAMCHI OCHIQ BURCHAKLI GLAUKOMA BILAN OG’RIGAN BEMORLARDA FIKSATSIYALANMAGAN KOMBINATSIYALANGAN TERAPIYA VA FIKSATSIYALANGAN KOMBINATSIYALANGAN TERAPIYANING KLINIK SAMARADORLIGINI QIYOSIY BAHOLASH

Relevance. The primary strategy for glaucoma treatment is the reduction of intraocular pressure (IOP) using topical ocular hypotensive medications; however, many patients require multiple drugs to achieve adequate IOP control. Purpose. To evaluate the efficacy and safety of a fixed combination of brinzolamide 1%/brimonidine 0.2% (FCBB) compared to the simultaneous administration of a non-fixed combination of brinzolamide 1% and brimonidine 0.2% in patients with primary open-angle glaucoma (POAG). Materials and methods. The study included 60 patients (120 eyes) with POAG, divided into two groups. The main group (n=30) received FCBB twice daily, while the comparison group (n=30) received a non-fixed combination of brinzolamide 1% and brimonidine 0.2% with a ≥10-minute interval between instillations. Efficacy was assessed by the dynamics of intraocular pressure (IOP) reduction on day 1, day 7, and at 1, 3, and 6 months of therapy. Tolerability and the incidence of adverse events were also evaluated. Results. Both treatment regimens resulted in a significant IOP reduction. In the FCBB group, IOP decreased by 26% at 8:00 and 31% at 10:00 on day 1. After 6 months, the reduction was 35% at 8:00 and 40% at 10:00, which was comparable to or slightly better than the results of the non-fixed combination group (32–39%). The incidence of adverse events was low in both groups. Conclusion. FCBB demonstrated highhypotensive efficacy and a favorable safety profile, providing stable IOP reduction with minimal side effects.

Hali tarjima qilinmagan